9 stories mentioning ASX:IMM
Every FINWIRES story that references ASX:IMM, newest first.
Immutep (ASX:IMM) said JPMorgan Chase & Co. and its affiliates ceased to be substantial holders of the company on June 5, according to a Wednesday Australian bourse filing.JPMorgan Chase & Co. and its affiliates became substantial holders on June 3 with a 5.2% voting power, an earlier filing showed.Immutep's shares were down past 2% in recent Wednesday trade.
Immutep (ASX:IMM) said a first-in-human phase one study evaluating IMP761, a potential therapeutic option for autoimmune diseases, met its primary endpoint, showing favorable safety and tolerability in healthy volunteers in the single ascending dose part of the study, according to a Thursday filing with the Australian bourse.IMP761 was designed to target activated T cells at inflammation sites to reduce pathological immune responses while preserving systemic immune function, the filing said.Early findings showed "significant and clinically relevant" pharmacodynamic activity, including the reduction of local inflammatory responses and attenuated T-cell activity compared with placebo across groups ranging from 0.9 milligrams per kilogram to 7 milligrams per kilogram, per the filing.Shares fell nearly 4% in morning trade Thursday.
Immutep (ASX:IMM) said a systematic evaluation of five clinical trials of eftilagimod alfa (efti), an antigen-presenting cell (APC) activator, in combination with standard-of-care therapies in late-stage cancer patients showed a significant increase in circulating absolute lymphocyte count (ALC) compared to standard-of-care alone, according to a Thursday Australian bourse filing.The company said increased ALC was significantly associated with improved clinical outcomes, with ALC responders in the efti plus standard-of-care group showing a clinically meaningful median overall survival improvement of 7.7 months compared to ALC non-responders, with no corresponding association observed in the standard-of-care alone group."The findings link the immune-activating effect of efti measured in patients' blood with meaningful and significant survival improvements observed in previous clinical trials," said Immutep's Chief Scientific Officer, Frederic Triebel, adding that the studies highlighted a key connection with efti's mechanism of action and clinical efficacy.The company's shares fell 2% in recent Thursday trade.
Immutep (ASX:IMM) received a notification from Nasdaq for not complying with the minimum bid price requirement for continued share listing, according to a Thursday Australian bourse filing.The closing bid price of the company's American depositary shares (ADS) failed to meet the $1-per-share minimum for 30 consecutive business days ended April 24, per the notification.The company said the notification has no immediate effect on the listing or trading of its ADSs, as Nasdaq has provided an initial compliance period of 180 calendar days expiring on Oct. 26 to regain compliance.Compliance can be regained if the closing bid price of the ADSs is at least $1 per share for a minimum of 10 consecutive business days during the compliance period, the filing added.The company said it intends to monitor the bid price and consider available options, noting that there can be no assurance that compliance will be regained.The company's Nasdaq-listed shares were last trading at $0.48 and have fallen more than 72% over the last 12 months.The company's Australian shares were down nearly 8% in recent Thursday trade.
Immutep (ASX:IMM) received notice that Bank of New York Mellon and its affiliated entities increased their holdings in the company to 21.11% from 20.08%, according to a Monday filing with the Australian bourse.Bank of New York Mellon and its affiliates now owns over 311 million shares in the company, the filing said.
Immutep (ASX:IMM) received notice that JPMorgan Chase and its affiliates decreased their holdings in the company to 5.88% from 6.89%, according to a Monday Australian bourse filing.JPMorgan Chase and its affiliates now owns 86.7 million shares in the company, the filing said.
Immutep (ASX:IMM) said JPMorgan Chase and its affiliates cut their stake in the company on Tuesday to 5.43% or about 80.1 million shares from 6.94% or roughly 102.3 million shares, according to a Friday filing with the Australian bourse.Shares of Immutep were down 9% in recent Friday trade.
Immutep (ASX:IMM) said the US Food and Drug Administration (FDA) granted orphan drug designation for its eftilagimod alfa drug candidate for the treatment of soft tissue sarcoma, according to a Wednesday Australian bourse filing.The investigator-initiated phase II EFTISARC-NEO trial, which was evaluating eftilagimod alfa in combination with radiotherapy and KEYTRUDA in the neoadjuvant setting in patients with resectable soft tissue sarcoma, met its primary endpoint, demonstrating a median tumor hyalinization/fibrosis of 51.5%.Its shares soared 41% in recent trading on Wednesday.
Immutep (ASX:IMM) said JPMorgan and its affiliates have reduced their stake in the company on April 8 to 6.94% or 102.3 million shares from 8.28% or 122.0 million shares, according to a Monday Australian bourse filing.The company's shares were down 10% on market close.